An Extension to Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis B
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the safety of telbivudine for up to 21 months of open-label
treatment in patients with chronic hepatitis B who have completed the CLDT600A2407 trial.
Patients treated with telbivudine during core phase will continue telbivudine and patients
treated with entecavir during core phase will be switched to telbivudine if the patient is
willing to enroll this study.